Alnylam Pharmaceuticals (NASDAQ:ALNY) : On Wednesday, The money flowed into the Alnylam Pharmaceuticals (NASDAQ:ALNY) stock with an uptick to downtick ratio was recorded at 1.12. Transactions worth $9.37 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $8.33 million. The total money flow into the stock was $1.03 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.01 million of block transactions on upticks. The total money flow in block trades was $0.01 million. In terms of price action, Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down $0.02 during the session at $55.28. Compared to the previous days closing, the stock was down only by -0.04%. For the week, the stock is 1.79%, over previous weeks closing.
In an insider trading activity,The director officer (Chief Executive Officer) of Alnylam Pharmaceuticals, Inc., Maraganore John sold 30,151 shares at $67.87 on April 19, 2016. The Insider selling transaction had a total value worth of $2,046,348. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 4% of Alnylam Pharmaceuticals shares according to the proxy statements. Institutional Investors own 83.74% of Alnylam Pharmaceuticals shares.
The company shares have dropped -52.96% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $137.89 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $60.42 and the 200 Day Moving Average price is recorded at $67.31. Alnylam Pharmaceuticals (NASDAQ:ALNY): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $56.22 and $53.63 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $56.99. The buying momentum continued till the end and the stock did not give up its gains. It closed at $55.60, notching a gain of 0.54% for the day. The total traded volume was 831,766 . The stock had closed at $55.30 on the previous day.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.